Last $4.12 USD
Change Today -0.02 / -0.48%
Volume 2.2M
ARNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:59 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6154 Nancy Ridge Drive

San Diego, CA 92121

United States

Phone: 858-453-7200

Fax: 858-453-7210

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. Clinical-Stage Programs BELVIQ for Chronic Weight Management BELVIQ (lorcaserin HCl), the company’s internally discovered drug for chronic weight management, is its first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration (FDA) for marketing in the United States and was made available by prescription in 2013 to adults who are overweight with a comorbidity or obese. The FDA’s approval was subject to the scheduling of BELVIQ by the US Drug Enforcement Administration. Arena GmbH has granted Eisai (Eisai Inc. and its parent, Eisai Co., Ltd.) exclusive commercialization rights for BELVIQ to all of the countries in the world, except for South Korea, Taiwan, Australia, New Zealand, and Israel. Arena GmbH also has marketing and supply agreements with Ildong Pharmaceutical Co., Ltd. (Ildong) for BELVIQ in South Korea, and with CY Biotech Company Limited in Taiwan. The company intends to enter into additional collaborative agreements for the regulatory approval and commercialization of BELVIQ in Australia, New Zealand, and Israel. The company planned to initiate a Phase 2 clinical trial to evaluate the potential of BELVIQ as a drug candidate for smoking cessation in 2014. The company has completed an initial study to evaluate the safety, tolerability and pharmacokinetic properties of different formulations of BELVIQ 20 mg extended release tablets, and selected a once-daily formulation for further development. BELVIQ Intellectual Property: As of February 17, 2014, the company owned issued patents that cover compositions of matter for the BELVIQ new chemical entity and related compounds and methods of treatment utilizing BELVIQ and related compounds in 69 jurisdictions, including the United States, Japan, Germany, France, China, Italy, Spain, Canada, the United Kingdom, Russia, Australia, India, and South Korea; and had applications pending in 2 other jurisdictions, of which the 1 with the primary pharmaceutical market was Brazil. As of February 17, 2014, the company owned registered trademarks on the use of the name BELVIQ in Class 5 for the sale and marketing of pharmaceutical preparations for weight management, weight loss, the treatment of obesity and the maintenance of weight loss in 101 jurisdictions, including the United States, Japan, Germany, France, China, Italy, Spain, the United Kingdom, Russia, Australia and South Korea; and had trademark applications pending in 42 other jurisdictions, of which the 3 with the primary pharmaceutical markets were Canada, Brazil, and India. The trademark on the name BELVIQ registered by the US Patent and Trademark Office has serial number US 4,080,253, while the corresponding trademark registered by the European Union’s Office for Harmonization in the Internal Market has serial number CTM 010224905. As of February 17, 2014, the company also filed trademark applications in Class 5 on one or more transliterations of the name BELVIQ in the local character set or alphabet of 24 jurisdictions, including Japan, China, Russia, and South Korea. APD811 Program APD811, an orally available agonist of the prostacyclin, or IP, receptor, is an internally discovered investigational drug candidate intended for the treatment of pulmonary arterial hypertension. The company was planning to initiate a Phase 2 clinical trial of APD811 in 2014. APD811 Intellectual Property: As of February 17, 2014, the company owned pending patent applications and patents covering compositions of matter for APD811 and related compounds and methods of treatment utilizing APD811 and related compounds, synthetic routes and intermediates useful in the manufacturing of APD811, and various solid state forms of APD811 filed in 19 jurisdictions, including the United States, Europe, Japan, China, Canada, Brazil, Russia, Australia, India, and South Korea. Temanogrel Program Temanogrel, an orally available inverse agonist of the

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNA:US $4.12 USD -0.02

ARNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.29 USD +0.18
Array BioPharma Inc $3.95 USD +0.03
Progenics Pharmaceuticals Inc $7.23 USD +0.15
Rigel Pharmaceuticals Inc $2.28 USD +0.26
Spectrum Pharmaceuticals Inc $7.38 USD +0.02
View Industry Companies
 

Industry Analysis

ARNA

Industry Average

Valuation ARNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.5x
Price/Book 11.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.